Drug target · HTR2B

5-HT2B

5-hydroxytryptamine receptor 2B

4 compounds in the CNS pipeline act on 5-HT2B.

Compounds targeting 5-HT2B

CompoundActionAffinityLead programDeveloper
Brilaroxazine (RP5063)Small moleculeAntagonistKi 0.19 nMPhase 3SchizophreniaReviva Pharmaceuticals Holdings, Inc.
Psilocybin (COMP360)PsychedelicAgonistpKi 8.33Phase 3Treatment-resistant depressionCOMPASS Pathways plc
Luvesilocin (RE104)PsychedelicAgonist—Phase 2Postpartum depressionReunion Neuroscience Inc.
Zalsupindole (DLX-001)Small moleculeAntagonist—Phase 1Major depressive disorderDelix Therapeutics, Inc.